Startup Creates Pill That Makes Fat Cells Burn Calories While You're at Rest
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
In the coming years, losing weight might be as simple as taking a pill.
A biotech startup based in Uruguay has successfully completed early-stage human trials for a first-in-class drug that targets fat cells to burn more calories, even while the body is at rest.
Developed by Eolo Pharma, the compound—known as SANA—could be a crucial breakthrough in metabolic therapy.
Unlike traditional obesity drugs that suppress appetite, SANA stimulates energy expenditure in fat tissue.
In the June 2025 edition of Nature Metabolism, researchers reported that the drug led to reduced body mass index (BMI) and improved blood glucose levels in just 15 days, with no serious side effects observed.
Stock image of someone standing on weighing scales.
Stock image of someone standing on weighing scales.
Photo by Liudmila Chernetska / Getty Images
Why It Matters
Obesity and type 2 diabetes continue to strain healthcare systems worldwide. Current treatments, like GLP-1 agonists, offer weight loss by reducing appetite but have been linked to gastrointestinal side effects.
SANA, by contrast, works by improving the body's ability to burn energy through a novel mechanism that activates creatine-dependent thermogenesis in fat tissue.
"Instead of telling the body to eat less, this drug tells the body to burn more," Carlos Escande, a researcher at the Institut Pasteur and a founding member of Eolo Pharma, said in a press release.
"It opens a completely new therapeutic pathway for obesity and metabolic disorders."
What To Know
The phase 1A/B clinical trial was conducted in healthy lean volunteers and individuals with overweight or obesity.
Over 15 days, participants receiving SANA at the highest dose (200 mg twice daily) experienced a weight reduction of up to 3% and improvements in insulin sensitivity.
According to the trial's registry, no severe adverse events occurred, and only minor side effects such as headache and soft stools were reported.
According to the release, SANA is the first drug developed entirely within Uruguay to reach this stage of testing.
In an email to Newsweek, Escande explained, "There were two main drivers of our work. First, the fact that when we started our research in 2014, there were no available treatments, and we were convinced that our molecules could provide an answer.
"Second, we were aware that developing a drug from South America was a challenge by itself. There are no records of this as far as we know.
"This challenge gave us the inspiration to follow this dream, to try to defeat the odds that were against us. The rest is a combination of extraordinary teamwork, good science and perseverance."
What People Are Saying
Escande told Newsweek that the accomplishment was a matter of pride for their international team: "The main reason for this feeling is that Uruguay—as well as many other countries in South America, especially Brazil and Argentina—have a strong scientific community that is capable of generating high-quality science.
"However, we still have a lot of work to do in terms of adding value to our knowledge. Indeed, the vast majority of our income comes from commodity exports.
"We believe that Eolo and the development of MVD1 might be a proof of concept that we are capable of more, and that the global industry should start paying attention to our region."
What's Next
The drug's success in phase 1 trials has paved the way for a broader phase II trial, scheduled to begin by the end of 2025.
That study will include more participants and incorporate patients diagnosed with type 2 diabetes.
If future trials confirm the results, SANA could become the first clinically approved drug to induce thermogenesis in humans by activating the creatine cycle, offering a novel treatment for a global epidemic with few sustainable solutions.
"Our dream is that MVD1 will, sooner or later, be able to reach the patients that may need it," Escande told Newsweek.
"The path that we have ahead of us is still challenging, and [there is] no doubt that we will need to partner with global companies to achieve our final goal. We are confident that we will be able to make it."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
2 minutes ago
- Medscape
GLP-1 Users May Face Optic Nerve Damage Risk in First Year
TOPLINE: The use of GLP-1 receptor agonists, and particularly liraglutide, was associated with an increased risk of developing nonarteritic anterior ischemic optic neuropathy (NAION) during the first year of treatment, with the risk being most pronounced in individuals without type 2 diabetes (T2D) or obesity. METHODOLOGY: Researchers conducted a case-control study to examine the association between the use of GLP-1 agents and development of NAION. They analyzed data from 65,612 patients with NAION who had obesity, T2D, or neither and matched them with 641,751 control participants by age, exact year of insurance enrollment, and history of T2D or obesity. Exposure to GLP-1 was defined by use (ever or never) and duration of continuous use (1, 2, or ≥ 3 years), according to dispensed prescriptions for dulaglutide, liraglutide, semaglutide, or exenatide. TAKEAWAY: The use of any GLP-1 agent was associated with 19% higher odds of developing NAION in the first year (odds ratio [OR], 1.19; 95% CI, 1.02-1.39), with the use of liraglutide tied to an even greater risk for the condition (OR, 1.53; 95% CI, 1.18-1.98). The association between exposure to a GLP-1 drug and development of NAION was stronger in people without T2D or obesity using any of these medications (OR, 2.03; 95% CI, 1.07-3.85) and especially liraglutide (OR, 2.32; 95% CI, 1.04-5.20). IN PRACTICE: 'The aforementioned associations for extended semaglutide use and liraglutide use among individuals without obesity or T2D are interesting, given these medications are increasingly being used for weight management,' the researchers reported. 'Future research including reasons for GLP-1RA [receptor agonists] use among this group and larger sample sizes could clarify whether these associations exist in this population or result from obesity or T2D diagnosis exposure misclassification or low exposure prevalence in this study,' they added. SOURCE: This study was led by Pallavi Nagdeve, MPH, and Russell Griffin, PhD, of the University of Alabama in Birmingham, Alabama. It was published online on July 24, 2025, in JAMA Ophthalmology. LIMITATIONS: The use of standard diagnostic codes may have led to misclassification of other optic neuropathy cases as NAION. Information available from the database used in this study was limited, and the reported associations may have been biased by unknown factors. DISCLOSURES: This study did not report any source of funding. The authors reported having no relevant financial conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Newsweek
31 minutes ago
- Newsweek
US Sends Icebreaker to Arctic Amid China Rivalry
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A Newsweek map shows that both the United States and China have deployed icebreakers to Arctic waters north of Alaska recently, as the two powers jostle for dominance in the region. USCGC Healy—America's largest and most technologically advanced icebreaker—is conducting a mission to reinforce U.S. presence in the Arctic, the U.S. Coast Guard said. Regarding the deployment of the Chinese icebreaker Xue Long 2, the Chinese Embassy in Washington, D.C., told Newsweek that China has always conducted normal maritime activities in accordance with international law. Why It Matters China has claimed the status of a "near-Arctic state" and a stakeholder in Arctic affairs. In recent years, the East Asian power has gradually expanded its Arctic presence, including deploying icebreakers and conducting scientific research with potential military applications. Alarmed by China's activities in the Arctic—which include its cooperation with Russia—the Pentagon has updated its Arctic strategy, calling for a greater military presence, enhanced intelligence capabilities and closer cooperation with allies to address these challenges. What To Know Using open-source data, the Healy was tracked departing Dutch Harbor—a key fishing port on Alaska's Amaknak Island—on July 13. Four days later, it transited the Bering Strait, which separates Alaska from Russia's Far East, during its northbound voyage. A Newsweek map shows that the Xue Long 2—China's first domestically built icebreaker—passed through the waterway a day after the Healy's transit. As of July 26, both vessels were tracked underway in Arctic waters on the U.S. Extended Continental Shelf (ECS)—an area of continental shelf extending beyond 230 miles from America's coastline, where the U.S. has exclusive rights to conserve and manage resources. The Healy was also observed sailing in the Chukchi Sea—north of the Bering Strait—and the Bering Sea on July 5 and July 9, respectively, according to photos released by the U.S. Coast Guard. The vessel departed its home port of Seattle, Washington, on June 19 to conduct what the U.S. Coast Guard described as "high-latitude science and research missions" in the Arctic. In a Facebook post on Monday, the U.S. Coast Guard said the Healy recently began its annual Arctic deployment, aimed at conducting "vital research" on sea ice and ocean movement. The United States Coast Guard icebreaker USCGC Healy transits southbound in the Chukchi Sea during its Arctic deployment on July 5, 2025. The United States Coast Guard icebreaker USCGC Healy transits southbound in the Chukchi Sea during its Arctic deployment on July 5, 2025. Petty Officer 1st Class Steve Strohmaier/U.S. Coast Guard The Newsweek map also shows that the Xue Long 2 remained outside the U.S. Exclusive Economic Zone (EEZ) around Alaska—extending up to 230 miles from the coastline—during its transit, except for a portion of its voyage in the Chukchi Sea prior to reaching the U.S. ECS. What People Are Saying The U.S. Coast Guard wrote in a Facebook post on Monday: "For over 234 years, the American people have relied on the Coast Guard to safeguard our national security, sovereignty, and economic prosperity. Through historic investment in the Coast Guard, we are expanding our icebreaker fleet to ensure American access, security, and leadership in the Arctic." The Chinese Embassy in Washington, D.C., told Newsweek on Tuesday: "China has always conducted normal maritime activities in relevant waters in accordance with international law, including the United Nations Convention on the Law of the Sea. We hope the parties concerned will view this matter in a proper manner, without undue suspicion or groundless speculation." What Happens Next It remains to be seen whether the U.S. will further strengthen its presence in the Arctic amid China's growing activities, with climate change having made the region more accessible.
Yahoo
7 hours ago
- Yahoo
LipoVive Releases Ingredient Report Comparing Natural GLP-1 Support to Synthetic Drugs Like Mounjaro
A Plant-Based Formula With Science-Referenced Compounds Designed to Support Hormonal Weight Balance Without Prescription Medications New York, July 29, 2025 (GLOBE NEWSWIRE) -- Disclaimer: The information provided in this article is for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment. Always consult with a licensed healthcare provider before beginning any new supplement or wellness routine. Trademark Disclaimer: Mounjaro® is a registered trademark of Eli Lilly and Company. This article and the product discussed herein are not affiliated with, endorsed by, or approved by Eli Lilly. The mention of Mounjaro is for informational and comparative purposes only, to provide readers with contextual background regarding GLP-1 and GIP mechanisms. In response to the surge in interest around GLP-1-based medications like Mounjaro® and the rise in consumer searches for 'natural Mounjaro alternatives,' the team behind LipoVive has published a new ingredient-focused report. The editorial examines how botanical compounds and minerals may support similar hormonal pathways involved in appetite regulation, metabolic thermogenesis, and blood sugar balance — without requiring synthetic drugs or injections. to explore the full breakdown of these ingredients and how they compare to synthetic GLP-1 strategies. The announcement comes amid heightened public interest in hormone-based weight management strategies. GLP-1 (Glucagon-like peptide-1) and GIP (Gastric inhibitory polypeptide) are two of the most researched hormones tied to satiety and insulin response. While prescription medications stimulate these receptors pharmacologically, many consumers are now exploring non-pharmaceutical routes that offer comparable metabolic support using ingredients derived from herbs, minerals, and antioxidant-rich extracts. A Science-Aligned Approach to Hormone-Supportive Weight Management Unlike traditional stimulant-based weight loss supplements, LipoVive is formulated to support the body's natural hormonal rhythm. Its six active ingredients — magnesium, zinc, chrysin, Tribulus terrestris, Chinese hawthorn, and saw palmetto — are selected to work synergistically across multiple metabolic touchpoints. The company's new report outlines how these ingredients may align with GLP-1 and GIP signaling goals, including support for: Improved insulin sensitivity Reduced appetite and cravings Enhanced thermogenesis and fat oxidation Regulation of core body temperature for metabolic activation Explore the Science Behind LipoVive's Natural Hormonal Support By framing the discussion through a science-forward lens, the report aims to inform consumers about viable, nature-based strategies that complement — rather than replace — mainstream options. Understanding GLP-1, GIP, and the Role of Hormonal Signals in Metabolism GLP-1 (Glucagon-like peptide-1) and GIP (Gastric inhibitory polypeptide) are naturally occurring hormones that play a key role in how the body manages hunger, insulin response, and fat storage. These incretin hormones help regulate: Post-meal blood sugar levels Satiety signals to the brain Rate of fat oxidation Storage and utilization of energy Synthetic GLP-1 receptor agonists like Mounjaro® and Ozempic® mimic these hormones and are commonly prescribed to address obesity and type 2 diabetes. However, due to cost, access restrictions, and the potential for side effects such as nausea or muscle loss, consumers are increasingly searching for natural compounds that may support similar pathways without synthetic intervention. LipoVive was developed in response to this growing demand. Rather than flood the system with synthetic analogues, LipoVive is designed to help the body regulate its own hormonal activity — with ingredients selected to support core metabolic processes LipoVive's Natural Ingredients Compare to Synthetic GLP-1 Agonists Unlike prescription medications that require injections and work by overriding the body's natural hormonal rhythms, LipoVive takes a gentler approach — supporting the same metabolic goals through carefully selected nutrients and botanicals. The formula includes six active ingredients, each chosen for its potential role in appetite regulation, insulin sensitivity, and fat metabolism: Magnesium – Supports energy production, insulin signaling, and carbohydrate processing, all of which are targeted by GLP-1 medications. Zinc – Contributes to enzymatic function and hormone balance. It plays a role in appetite regulation and has been linked to improved fat oxidation. Tribulus Terrestris – Traditionally used for vitality, this adaptogen may support hormonal balance and physical energy levels, which can enhance the body's natural fat-burning capacity. Chrysin – A flavonoid studied for its antioxidant and hormone-modulating effects, chrysin may assist with reducing oxidative stress and maintaining lean body mass. Saw Palmetto Extract – Commonly used for endocrine support, saw palmetto may help maintain healthy androgen levels — relevant to fat storage and metabolism. Chinese Hawthorn (Crataegus pinnatifida) – Used in traditional medicine for digestion and circulation, this botanical may help improve lipid profiles and nutrient delivery. Together, these ingredients aim to support similar outcomes to synthetic drugs like Mounjaro — without injections, prescriptions, or synthetic Core Body Temperature Plays a Role in Fat Metabolism Recent research suggests that internal body temperature may play a critical role in metabolic efficiency. Individuals with consistently low core temperatures often experience slower metabolic rates, reduced fat-burning capacity, and stubborn weight retention — even when following strict diet and exercise routines. This concept ties into thermogenesis, the body's process of generating heat to burn energy. When thermogenesis is sluggish, fat oxidation slows. Conversely, mild increases in internal temperature can stimulate brown adipose tissue activity, helping the body convert stored fat into usable energy. LipoVive incorporates non-stimulant ingredients that may assist in gently raising internal temperature. Rather than using caffeine or harsh thermogenics, the formula leverages botanical extracts and minerals that support both warmth and metabolic balance — a dual approach for individuals who struggle with cold extremities, slow digestion, or weight plateaus. By supporting hormonal alignment and encouraging mild thermogenesis, LipoVive provides a unique angle on natural weight support — one that goes beyond the one-dimensional strategies of many over-the-counter fat Sets LipoVive Apart from Stimulant-Based Fat Burners Many popular fat-burning supplements rely on caffeine, diuretics, or artificial appetite suppressants to produce short-term effects. While these compounds can lead to temporary weight loss or water reduction, they often fail to address the underlying hormonal imbalances that make fat loss difficult — especially for adults over 35. LipoVive takes a different approach. Instead of artificial spikes in energy or metabolism, the formula focuses on restoring natural balance across multiple systems: Hormonal alignment through magnesium, zinc, and adaptogenic herbs Thermogenic support without jitters or crashes Improved digestion and circulation, which may help with nutrient delivery and fat metabolism This makes LipoVive appealing to individuals who are sensitive to stimulants, those experiencing hormonal changes related to age, or anyone seeking long-term support over quick fixes. Its formulation — including non-GMO ingredients, U.S.-based manufacturing, and third-party testing — reinforces its positioning as a wellness-forward solution for metabolic and GIP: Two Hormones at the Center of Today's Weight Loss Conversation Glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) are two of the most researched metabolic hormones in modern medicine. These naturally occurring compounds play crucial roles in regulating appetite, blood sugar, and fat storage — making them central targets in today's pharmaceutical weight loss solutions. Synthetic drugs like Mounjaro® function by artificially activating GLP-1 and GIP receptors. This stimulation reduces appetite, slows digestion, and improves glucose handling — leading to measurable weight loss. However, the cost, injection requirements, and potential side effects have led many to seek alternatives. LipoVive offers a different strategy: support the body's own GLP-1 and GIP signaling systems using nutrients and botanical compounds shown to influence these pathways naturally. Emerging research highlights that certain plant-based ingredients may: Encourage natural GLP-1 production Improve post-meal blood sugar control Enhance satiety signals without synthetic intervention LipoVive's formulation embraces these mechanisms while avoiding pharmaceutical dependence — offering consumers a gentle, hormone-aligned approach to weight Comparison: Natural vs. Synthetic Approaches to GLP-1 Support With synthetic GLP-1 receptor agonists dominating headlines — including injections like Mounjaro® and Wegovy® — consumers are increasingly curious about natural ways to support similar metabolic functions without pharmaceutical intervention. Below is a direct comparison between drug-based strategies and LipoVive's botanical pathway: Synthetic GLP-1 Drugs (e.g., Mounjaro®) Mechanism: Artificially mimic GLP-1 and GIP hormones Delivery: Typically injectable, requiring medical supervision Effects: Rapid appetite suppression and weight loss Limitations: High cost, potential digestive side effects, long-term dependency LipoVive Natural Support Mechanism: Encourages the body's own hormone balance via micronutrients and botanicals Delivery: Capsule form; taken orally once per day Effects: Gradual appetite control, metabolic support, thermogenesis Strengths: Caffeine-free, non-GMO, no injections, gentle on digestion LipoVive's six core ingredients include: Magnesium – Supports insulin sensitivity and metabolic enzyme function Zinc – Critical for hormone production and satiety signaling Tribulus Terrestris – Traditional vitality enhancer tied to fat metabolism Chrysin – Antioxidant flavonoid that may regulate hormonal feedback Saw Palmetto – Promotes endocrine balance Chinese Hawthorn – Aids digestion, circulation, and lipid regulation Together, these ingredients form a non-stimulant matrix that supports natural weight management through hormonal and thermogenic LipoVive May Be Safer for Long-Term Use Than Stimulant-Based Fat Burners One of the biggest challenges in the supplement industry is finding solutions that are both effective and sustainable. While many fat burners rely on stimulants like caffeine or yohimbine, LipoVive takes a different approach — prioritizing internal hormone balance over short-term energy spikes. This distinction is especially important for individuals who: Experience side effects from stimulants Struggle with appetite regulation and insulin sensitivity Are looking for a gentler, longer-term strategy that works with the body — not against it LipoVive's formula avoids the use of caffeine, diuretics, and harsh appetite suppressants. Instead, it includes ingredients known for: Gently raising core body temperature to support thermogenesis Encouraging satiety and metabolic balance via micronutrient pathways Supporting natural GLP-1 and GIP signals without disrupting endocrine rhythms By offering this kind of dual-action support — hormonal and thermogenic — LipoVive positions itself as a daily-use supplement that's both well-tolerated and scalable over Asked Questions About LipoVive and Natural GLP-1 Support As public awareness of GLP-1 hormone science grows, many consumers are turning to ingredient-based solutions like LipoVive. Below are answers to some of the most common questions related to the product and its function. What does LipoVive actually do?LipoVive supports the body's own GLP-1 and GIP pathways—two natural hormones involved in hunger regulation, fat metabolism, and insulin sensitivity. Its formula includes minerals, adaptogens, and thermogenic ingredients to help balance these systems. Is LipoVive a drug or medication?No. LipoVive is a dietary supplement and does not contain synthetic GLP-1 agonists. It is not a replacement for Mounjaro®, Ozempic®, or any prescription treatment, and is intended for general wellness support only. When can users expect results?Most individuals report improved appetite control, digestion, and energy within the first two weeks. Visible weight management benefits typically take 4–8 weeks when used consistently with lifestyle support. Are there side effects?LipoVive does not contain caffeine, synthetic stimulants, or common allergens. The majority of users tolerate it well. As with any supplement, users should consult a healthcare provider before beginning use, especially if they have a medical condition. How is LipoVive taken?One capsule per day with water, preferably in the morning. No cycling or loading phases are required. Where is LipoVive manufactured?It is produced in the United States in GMP-certified, FDA-registered facilities using non-GMO ingredients and third-party testing protocols. Is it available in stores?No. LipoVive is exclusively available through its official website, which helps ensure product authenticity and includes digital health bonuses. Digital Wellness Bonuses Included With Select LipoVive Packages To further support individuals exploring natural metabolic health strategies, the creators of LipoVive now include several digital bonus guides with qualifying orders. These educational resources are designed to complement the supplement's GLP-1-aligned formulation and offer practical tools for whole-body wellness. Bonus #1: Detox Gut Cleanse — 'Go Every Day' ProtocolA step-by-step guide designed to support digestive regularity and reduce bloating using natural herbs, hydration strategies, and fiber-rich foods. This protocol pairs well with LipoVive's hormonal focus for more complete metabolic alignment. Bonus #2: Fortifying Smoothies — Recipes for Circulation SupportThis collection of anti-inflammatory, antioxidant-rich smoothie recipes is designed to improve nutrient absorption and promote better blood flow—critical factors for metabolic efficiency and fat mobilization. Bonus #3: The Apple Trick — A Tonifying Tonic for Blood Sugar SupportA fruit-based recipe that supports insulin sensitivity and hydration. While not a treatment or cure, this blend aligns with LipoVive's approach to natural blood sugar balance. Bonus #4: The Secret Indian Cocktail — Adaptogenic Support for Mood and MotivationThis tonic draws on traditional Ayurvedic ingredients to help regulate stress-related eating, nighttime cravings, and emotional well-being. It supports overall motivation and resilience during lifestyle changes. These digital resources are delivered instantly after checkout with eligible multi-bottle LipoVive Thoughts on LipoVive's Natural Metabolic Support Strategy Rather than relying on a single 'hero ingredient,' LipoVive's formula reflects a synergistic blend of botanical and mineral-based compounds. By combining nutrients like magnesium, zinc, Tribulus terrestris, chrysin, saw palmetto, and Chinese hawthorn, the supplement is designed to align with GLP-1 and GIP-related metabolic pathways — without synthetic intervention or stimulants. This multi-pronged approach highlights a growing interest in natural hormonal balance, internal thermogenesis, and non-pharmaceutical appetite regulation — positioning LipoVive as part of a larger conversation around lifestyle-friendly metabolic support and Important Notices The information provided in this article is for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment. Always consult with a licensed healthcare provider before beginning any new supplement or wellness routine. Mounjaro® is a registered trademark of Eli Lilly and Company. This article and the product discussed herein are not affiliated with, endorsed by, or approved by Eli Lilly. The mention of Mounjaro is for informational and comparative purposes only, to provide readers with contextual background regarding GLP-1 and GIP mechanisms. Statements in this article have not been evaluated by the Food and Drug Administration. Products referenced are not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary. Always follow label directions and consult with a licensed professional before using any dietary supplement. To learn more about LipoVive or to explore its full ingredient profile, visit the official site here: CONTACT: Email: support@ Phone: (970) 406-7582Sign in to access your portfolio
